The Dutch competition authority, in collaboration with the National Health Care Institute and the Dutch Healthcare Authority, commissioned a study by Radboudmc to gauge public opinion on the pricing of expensive prescription drugs. The findings indicate that while citizens recognize the importance of these drugs, they are unwilling to accept exorbitant prices.

In a citizens' forum and a national survey, participants expressed their willingness to pay higher prices for drugs that provide significant health benefits or improve quality of life. However, they are critical of prices that lack transparency, especially when the efficacy or safety of the drugs is uncertain or when the innovations are marginal compared to existing treatments.

This initiative marks a significant shift in the Netherlands, as it is the first time citizens have been actively involved in discussions about drug pricing. The insights gathered will inform recommendations to be presented to the Ministry of Health, Welfare, and Sport in the fall of 2025, aiming to establish a framework for socially acceptable drug prices.

The study highlights a societal demand for transparency in drug pricing and a critical evaluation of the costs associated with prescription medications. The recommendations will also focus on promoting healthy competition within the pharmaceutical sector to ensure affordability and accessibility for patients.